Climb Bio — Third Quarter 2026 Earnings Summary

Climb Bio reported third-quarter 2026 financial results showing $227.6 million in cash and marketable securities, with an expected runway into the second half of 2028. The company initiated dosing in the NAVIGATE-2 Phase 2 trial for its CLYM116 program in IgA nephropathy, supported by Phase 1 data demonstrating sustained APRIL suppression and Gd-IgA1 reduction suitable for every-12-week dosing. Initial data from the PrisMN Phase 2 trial for budoprutug in primary membranous nephropathy showed B-cell depletion and immunologic remission at 200 mg, while Phase 1b data in systemic lupus erythematosus indicated a favorable safety profile and dose-dependent B-cell depletion. Additional clinical updates include ongoing trials for budoprutug in immune thrombocytopenia and plans to present further data at the American Society of Hematology meeting in December 2026.